A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · May 19, 2009

Keywords

ClinConnect Summary

This clinical trial is looking at how inflammatory bowel disease (IBD) affects pregnancy outcomes for women who have this condition. Researchers want to learn about the impact of medications and the level of disease activity during pregnancy on both the mothers and their babies. The study is taking place at the University of California San Francisco and 30 other locations across the United States. They are currently recruiting female participants who are pregnant and have a confirmed diagnosis of IBD, especially those who are taking medications to manage their condition.

To be eligible for this study, women must be pregnant and at least 18 years old, and they should have been diagnosed with IBD. However, those who are pregnant with twins or more will not be included. Participants in the study can expect to provide information about their health during pregnancy and may help researchers understand how IBD and its treatments influence pregnancy and neonatal outcomes over the first 18 years of their child’s life. This research could help improve care for future mothers with IBD.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female patients with confirmed IBD diagnoses who are pregnant and taking immunosuppressants and/or biologic therapy
• Exclusion Criteria:
• • Pregnant female patients younger than 18 years of age
• • Confirmed multiple gestation